Symic Biomedical Appoints Rinko Ghosh President and Chief Business Officer

SAN FRANCISCO, Jan. 7, 2016 /PRNewswire/ -- Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the appointment of Rinko Ghosh as President and Chief Business Officer.

Previously Mr. Ghosh was Senior Vice President & Chief Business Officer at Nektar Therapeutics. His primary responsibilities at Nektar included business and corporate development, marketing, strategic planning, portfolio evaluation and alliance management. He was a member of the Executive Committee at Nektar and was instrumental in closing large, revenue-generating transactions and building long-term alliances with Astra Zeneca, Baxter, Bayer, Novartis, Amgen, Roche, Pfizer, Merck, BMS, UCB, Covidien, Takeda/Affymax and Allergan/MAP. He has completed more than 50 business transactions over his career across North America, Europe and Asia. He has also been an Advisor to several Life Sciences companies, including Epic Sciences, PulmoKine, MannKind, Pearl Therapeutics (acquired by Astra Zeneca) and Aviron (acquired by MedImmune). Prior to joining Nektar in 2001, he was co-CEO of a biotechnology startup in Asia. Earlier, as a management consultant with A.T. Kearney and as a scientific consultant with Environ, he worked with multinational clients in healthcare and other industries.

"Rinko has more than 20 years of experience in biotechnology and healthcare and a proven track record of executing high-value transactions, building commercial expertise in innovation-based enterprises and driving strategic growth," said Ken Horne, Chief Executive Officer of Symic. "He is joining the Symic team at a pivotal time for the company, as we focus on achieving key clinical milestones and translating our novel platform candidates into therapeutic product opportunities, serving areas of high unmet medical need."

Mr. Ghosh earned his M.B.A. from the Wharton School, University of Pennsylvania, his M.S. in Environmental Engineering from Vanderbilt University, and his B.S. in Chemical Engineering from the Indian Institute of Technology, Bombay. Throughout his career, he has been actively involved with non-profits, including the Asian Art Museum of San Francisco. He has served on several non-profit boards where he has helped resolve issues related to board governance, fund-raising and strategic planning.

About Symic

Symic is a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, which are important structural and functional macromolecules native to the ECM, play a critical role in healing following injury and in chronic diseases. Symic's proprietary compounds function like proteoglycans, and have been designed to promote healing and repair in a variety of disease states. Symic's lead compound, SB-030, is currently under evaluation in the Phase 1/2 SHIELD clinical trial for vascular endothelial injury. In addition, Symic's osteoarthritis drug candidate, SB-061, is poised to enter the clinic in the next few months.

Symic is based in San Francisco. For additional information, please visit the company's website at or follow us on Twitter at and LinkedIn at

Media Contacts

David Schull or Lena Evans
Russo Partners, LLC
(212) 845-4271
(212) 845-4262
[email protected]
[email protected]

To view the original version on PR Newswire, visit: